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Abstract 22 
 23 
Class-switch recombination (CSR) is an essential B cell process that alters the isotype 24 
of antibody produced by the B cell, tailoring the immune response to the nature of the 25 
invading pathogen. CSR requires the activity of the mutagenic enzyme AID (encoded 26 
by AICDA) to generate chromosomal lesions within the immunoglobulin genes that 27 
initiate the class switching recombination event. These AID-mediated mutations also 28 
participate in somatic-hypermutation of the immunoglobulin variable region, driving 29 
affinity maturation. As such, AID poses a significant oncogenic threat if it functions 30 
outside of the immunoglobulin locus. We found that expression of the microRNA, miR-31 
29b, was repressed in B cells isolated from tonsil tissue, relative to circulating naïve B 32 
cells. Further investigation revealed that while enforced overexpression of miR-29b in 33 
human B cells precipitated a reduction in overall AID protein and a corresponding 34 
diminution in CSR to IgE, miR-29b knockdown in naïve B cells resulted in elevated 35 
AID expression. Similarly, miR-29b was able to directly interact with the AID 5’-UTR 36 
and modulate expression in reporter assays. Given miR-29b’s ability to potently target 37 
AID, a mutagenic molecule that can initiate chromosomal translocations and “off-38 
target” mutations, we propose that miR-29b acts to silence premature AID expression 39 
in naïve B cells, thus reducing the likelihood of inappropriate and potentially dangerous 40 
deamination activity. 41 
 42 
 43 
  44 
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1. Introduction 45 
 46 
During the course of the immune response, mature B cells undergo two diversification 47 
events at the immunoglobulin loci, somatic hypermutation (SHM) and class-switch 48 
recombination (CSR) (Stavnezer, 2011). SHM introduces mutations in the 49 
hypervariable loops of the antigen binding site, found within the CDRs of the 50 
Immunoglobulin Heavy (IGH) and light (IGL) chain variable regions. This allows for 51 
selection of B cell clones which harbour Igs with increased affinity for antigen, 52 
promoting the development of highly specific Ig molecules. In contrast, CSR replaces 53 
the Cμ and Cδ heavy chain gene exons (encoding IgM and IgD respectively) with the 54 
downstream C-region exons of the α, γ, or ε isotypes (encoding IgA, IgG and IgE) 55 
(Stavnezer and Schrader, 2014). This process, which is driven by cytokines released 56 
from T helper cell populations, ensures that the effector functions of the antibodies 57 
produced by B cells are tailored to the nature of the invading pathogen. Both CSR and 58 
SHM require the activity of the mutagenic enzyme, activation-induced cytidine 59 
deaminase (AID, encoded by AICDA) (Muramatsu et al., 2000; Revy et al., 2000). AID 60 
acts to deaminate deoxycytidine residues within the IG variable and the IGH constant 61 
regions, resulting in the production of deoxyuracils(Neuberger et al., 2003). In the case 62 
of SHM, the ensuing mismatches initiate low-fidelity DNA repair pathways leading to 63 
the incorporation of mutations within the IGH and IGL variable regions, whereas in 64 
CSR the mismatches trigger a deletional-recombination event that replaces the 65 
upstream “acceptor” C-region (initially Cμ and Cδ ) with a downstream “donor” C 66 
region (C1-4, C or C1-2) (Keim et al., 2013).  67 
 68 
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The mechanisms targeting AID to the Ig genes are incompletely understood. It has been 69 
proposed that transcriptional stalling (Pavri et al., 2010), the formation of RNA:DNA 70 
hybrids called R loops (Shinkura et al., 2003), the exosome (Basu et al., 2011), super-71 
enhancers (Qian et al., 2014), germline transcript RNA (Wang et al., 2015), 14-3-3 72 
adaptor proteins (Xu et al., 2010), as well as the sequence location of the Ig genes (Yeap 73 
et al., 2015), recruit AID to the DNA and promote deamination. However, AID activity 74 
is promiscuous, and deamination-induced mutations are detected at multiple non-Ig 75 
sites (M. Liu et al., 2008). This collateral damage has significant oncogenic potential, 76 
as demonstrated by AID-induced chromosomal translocations that occur in the context 77 
of genomic instability (Robbiani et al., 2008; 2009) and AID-induced mutations of non-78 
Ig genes (Duquette et al., 2005; Pasqualucci et al., 1998; 2001). Therefore, AID 79 
expression and activity must be carefully controlled.  80 
 81 
One mechanism by which cells are able to fine-tune their protein expression is through 82 
microRNAs (miRNAs), short non-coding RNAs that regulate gene expression by 83 
promoting mRNA decay and translational repression (Bartel, 2009). In mice miR-155 84 
has been shown to directly repress AID (Teng et al., 2008) and removing the miR-155 85 
binding site within the Aicda 3’ UTR increases the likelihood of AID-induced Igh-Myc 86 
chromosomal translocations (Dorsett et al., 2008), a transforming event frequently 87 
observed in Burkitt’s Lymphoma. Similarly, miR-181 can also directly target Aicda 88 
and is proposed to prevent inappropriate AID expression in the absence of B cell 89 
activation (de Yebenes et al., 2008). Although the miRNA-mediated regulation of AID 90 
expression has been well studied in mice, this mode of regulation has not been 91 
extensively studied in human B cells. 92 
 93 
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To identify miRNAs involved in coordinating the B cell response in humans, 94 
we analysed the published literature that had profiled the miRNA pool of distinct 95 
human B cell subpopulations (Basso et al., 2009; Malumbres et al., 2009; Tan et al., 96 
2009; J. Zhang et al., 2009). These studies consistently reported that the conserved 97 
miRNA miR-29b was less abundant in germinal centre B cells relative to naïve and 98 
memory cell compartments. Similarly, we show that miR-29b has diminished 99 
expression in B cells isolated from tonsil tissue relative to naïve B cells isolated from 100 
peripheral blood. It is of interest to note that miR29b expression has also been reported 101 
to be reduced in mantle cell lymphoma, a lymphoma thought to originate from Pre-GC 102 
mature B cells (Zhao et al., 2010).  In this report we investigate potential miR29b targets 103 
and demonstrate that it is able to directly target AICDA mRNA. Enforced 104 
overexpression of miR-29b in human B cells reduces overall AID protein and causes a 105 
corresponding diminution of CSR to IgE in vitro. Together, these results suggest that 106 
miR-29b is able to silence “leaky” expression of AID, limiting its expression to 107 
appropriately activated B cells and thus helping to maintain chromosomal integrity. 108 
  109 
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2. Materials and Methods 110 
 111 
2.1 Ethics 112 
Ethical approval was granted by London Bridge Research Ethics Committee for both 113 
peripheral blood donations (09/H0804/77 and 14/LO/1699) and for tonsil donations 114 
(08/H0804/94). Full written informed consent was obtained from all donors or the 115 
donors’ parents or legal guardian.  116 
 117 
2.2 B cell isolation, transfection and culture 118 
Naïve B cells were isolated from peripheral blood using the Naive B Cell Isolation Kit 119 
II (Miltenyi Biotec). B cells were isolated from tonsil tissue as previously described 120 
(Cooper et al., 2012). Briefly, mononuclear cells were isolated from dissected tonsil 121 
tissue on a density gradient (Lymphoprep, Axis-Shield PoC AS) followed by 122 
incubation with aminoethyl isothiouronium bromide-treated sheep red blood cells to 123 
rosette T cells. To overexpress miR-29b, 800 nM miR-29b Pre-miR miRNA Precursor 124 
(Thermo Fisher Scientific) or the equivalent non-targeting negative control molecules 125 
was delivered into 5 × 106 freshly isolated primary B cells using the Amaxa Human B 126 
cell Nucleofector Kit (LONZA). The Pre-miR miRNA Precursors used were 127 
proprietary short (16-28bp) double stranded RNA molecules chemically modified to 128 
ensure the desired strand is loaded into the RISC complex(Barnes et al., 2012). To 129 
inhibit miR-29b, 800 nM miR-29b of mirVana miRNA Inhibitor (Thermo Fisher 130 
Scientific) or the equivalent non-targeting negative control molecule was delivered into 131 
5 × 106 freshly isolated primary B cells using the Amaxa Human B cell Nucleofector 132 
Kit (LONZA). The mirVana miRNA Inhibitors used were single stranded, chemically 133 
modified RNA molecules designed to irreversibly bind and inhibit endogenous 134 
 7 
miRNAs (Barnes et al., 2012). Samples were nucleofected using program U-15 on the 135 
Nucleofector Device and cultured at a concentration 5 × 105 mL-1 in RPMI 1640, 10% 136 
HyClone Fetal Bovine Serum, 100 g/mL Streptomycin, 100 U/ml Penicillin, 2 mM L-137 
Glutamine. To stimulate CSR, the medium was supplemented with 1 mg/mL of 138 
anti-CD40 antibody, 200 IU/mL of recombinant human IL‐4, 5 mg/mL of insulin and 139 
35 mg/mL of transferrin. The human monoclonal IgM+ IgD+ CL01 B cell line (Cerutti 140 
et al., 1998) was cultured in RPMI 1640, 10% HyClone Fetal Bovine Serum, 100 141 
g/mL Streptomycin, 100 U/mL Penicillin, 2 mM L-Glutamine and kept at a 142 
concentration of between 1-5 × 105 cells/mL. To induce expression of AID, the culture 143 
medium was supplemented with 1 mg/mL of anti-CD40 antibody and 200 IU/mL of 144 
recombinant human IL-4. The CL01 cell line was nucleofected using the Amaxa Cell 145 
Line Nucleofector Kit V along with program C-09 on the Nucleofector Device. All 146 
cells were cultured in a humidified incubator at 37°C, 5% CO2. 147 
 148 
2.3 RNA Isolation and quantitative (q) RT-PCR analysis 149 
Total RNA was extracted from cultured cells using the miRNeasy Mini Kit with QIAzol 150 
Lysis Reagent (Qiagen). Residual gDNA was removed by incubating the extracted 151 
sample with 20 units of TURBO DNase enzyme (Thermo Fisher Scientific) at 37°C for 152 
one hour followed by a second phenol-chloroform cleanup. The integrity and yield of 153 
isolated RNA was checked on a 2100 Bioanalyzer (Agilent) using the RNA6000 Pico 154 
Assay. For analysis of mRNA expression, cDNA was generated from total RNA using 155 
random hexamers with RevertAid H Minus Reverse Transcriptase (Thermo Fisher 156 
Scientific) and all genes (with the exception of AICDA, εGLT, IgG and IgE) were 157 
detected expression using TaqMan MGB Gene Expression Assays (Thermo Fisher 158 
Scientific). The primer and probe set for AICDA was designed using the Universal 159 
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Probe Library Assay Design Centre (Roche) while the εGLT, IgG and IgE primer and 160 
probe sets were designed in house. Individual samples were subjected to qPCR and run 161 
in triplicate with TaqMan Universal Master Mix II on the ViiA 7 Real-Time PCR 162 
System using 18S rRNA as a normalization control and gene expression was 163 
determined using the 2-ΔΔCt method. For qRT-PCR analysis of miRNA expression, the 164 
TaqMan Small RNA Assay for miRNA quantification (Thermo Fisher Scientific) was 165 
used. This involved separate cDNA generation for each miRNA, utilising a miRNA-166 
specific, stem-loop primer to facilitate reverse transcription. The small nucleolar RNA 167 
RNU6B was used as a normalization control and gene expression was determined using 168 
the 2-ΔΔCt method.  169 
 170 
2.4 Gene expression arrays  171 
Fresh tonsil B cells were transfected with a miR-29b mimic or its associated negative 172 
control and cultured in class switching stimuli for 24 hours. RNA was isolated using 173 
the miRNeasy Mini Kit with QIAzol Lysis Reagent (Qiagen) and then DNase-treated 174 
as described. 10 ng RNA was amplified using the Ovation Pico WTA System V2 175 
(Nugen). 4 g of amplified single-stranded cDNA was biotin-labeled using the Encore 176 
BiotinIL Module (Nugen). Finally, transcriptomic analysis was performed by 177 
hybridizing 750 ng of biotin-labeled single-stranded cDNA onto a HumanHT-12 v4 178 
Expression BeadChip (Illumina) and scanned using the Illumina iScan System. QC 179 
analysis and RMA normalization was performed in Illumina’s Genome Studio Suite 180 
v1.0. Assessment of differential gene expression and statistical analysis was performed 181 
in Partek Genomics Suite version 6.6. Data from this study have been deposited in 182 
NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO 183 
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Series accession number GSE100735 184 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100735).  185 
Immunoblotting 186 
B cells were stimulated for 60 hours in class-switching stimuli following transfection. 187 
Cells were harvested in protein lysis buffer (pH 7.4, 25 mM Tris, 150 mM NaCl, 1 mM 188 
EDTA, 1% NP40, 5% Glycerol, 10% Roche Protease Inhibitor). Total protein levels 189 
were quantified using the bicinchoninic acid assay and approximately 50 ug protein 190 
lysate were run on SDS-polyacridimide gels. Following wet transfer onto nitrocellulose 191 
membranes, the membranes were probed with the following antibodies for protein 192 
expression (AID - EK2 5G9, STAT6 - D3H4, p-STAT6Tyr641 - C11A12, p38 MAPK - 193 
D13E1, p-p38Thr180/Tyr182 - D3F9, AKT - 40D4, p-AKTser 473 - D9E, GAPDH - 6C5), and 194 
images were developed using the Molecular Imager® ChemiDocTM XRS System (Bio‐195 
Rad). GAPDH (clone 6C5, Abcam) was used as a loading control.  196 
 197 
2.5 Luciferase Assays 198 
The region of the AICDA 3’ UTR encompassing the miR-29 binding site was subcloned 199 
into the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega), 200 
which harbours both a firefly luciferase reporter gene, for analysis of miRNA-mRNA 201 
binding site interactions, and a renilla luciferase reporter gene, which acts as a 202 
transfection efficiency control. For the mismatched construct, the miR-29 binding site 203 
in the AID 3’ UTR was replaced with a BamHI restriction site using sequential rounds 204 
of mutation cloning. HEK293T cells were seeded onto white 96-well tissue culture 205 
plates and having reached 70% confluence were transfected with 50 ng of one of the 206 
luciferase constructs and 10 nM of miR-29 mimic using Lipofectamine 2000 (Thermo 207 
Fisher Scientific). Reactions were performed in triplicate. Luciferase activity was 208 
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quantified after 24 hours on a GloMax-Multi Microplate Luminometer (Promega, 2 209 
seconds integration time) using the Dual-Glo Luciferase Assay System (Promega). The 210 
luciferase signal ratio was calculated by dividing firefly luciferase activity by renilla 211 
luciferase activity and normalized to cells transfected with an insert-free pmirGLO 212 
vector.  213 
 214 
2.6 Flow Cytometry 215 
Apoptosis staining was performed using the Annexin V Apoptosis Detection Kit 216 
(eBioscience). For cell proliferation analysis, 107 transfected CL01 cells were washed 217 
with PBS, resuspended in 1 mL PBS containing 1 M CellTrace Violet dye (Thermo 218 
Fisher Scientific), and left in the dark at 37°C for 10 minutes. The reaction was 219 
quenched by the addition of cell culture media. The cells were washed, resuspended 220 
and cultured in a 37°C incubator until analysis via flow cytometry. Intracellular 221 
antibody staining of IgG and IgE was performed as previously described16 using the a 222 
fixable viability stain (Zombie Aqua Thermo Fisher Scientific). 223 
  224 
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3. Results 225 
 226 
3.1 miR-29b is repressed in tonsil B cells relative to peripheral naïve B cells 227 
In order to identify dynamically regulated miRNAs within the context of mature human 228 
B cells, we analysed the available literature profiling the miRNA pool in different B 229 
cell subpopulations (Basso et al., 2009; Malumbres et al., 2009; Tan et al., 2009; J. 230 
Zhang et al., 2009). We observed that the evolutionarily conserved miRNA miR-29b 231 
was less abundant in germinal centre B cells relative to naïve and memory cell 232 
compartments (supplementary Fig. 1A & 1B). miR-29b is a member of the miR-29 233 
family, also including miR-29a and miR-29c, which share the same seed region and 234 
thus overlap in their predicted targets (Liston et al., 2012). Interestingly miR29c was 235 
also less abundant in GC B cells compared to naïve or memory compartments, 236 
potentially reinforcing the effects of this miRNA family (supplementary Fig. 1A & 1B). 237 
We analysed the abundance of miR-29b in B cells isolated from tonsils, a large 238 
proportion of which have a germinal centre phenotype (CD19+ CD38+ CD27- or CD19+ 239 
CD38+ CD27+) (supplementary Fig. 2A), and compared its prevalence to naïve B cells 240 
(CD19+ IgD+ CD27-) (supplementary Fig. 2B) isolated from peripheral blood. In line 241 
with previous reports(Malumbres et al., 2009), miR-29b was nearly 3 times more 242 
abundant in the circulating naïve B cells than in tonsil-derived B cells (Fig. 1). 243 
 244 
3.2 Identification of AICDA as a miR-29b target gene in human tonsil B cells 245 
To gain insight into the role of miR-29b in the context of B cell activation we 246 
overexpressed miR-29b in tonsil B cells and investigated global gene expression 247 
changes following 24 hours culture with IL-4 and anti-CD40 stimulation using Illumina 248 
BeadChip Microarrays (HumanHT-12 v4). Transfection of a miR-29b mimic into tonsil 249 
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B cells increased miR-29b abundance by approximately 15-fold 24 hours after 250 
transfection, compared to cells transfected with a negative control mimic molecule 251 
(supplementary Fig. 3A). No detectable difference was seen in cell viability between 252 
the miR29b mimic or negative control as judged by flow cytometry FSC/SSC although 253 
cell viability was reduced approximately 2 fold compared to un-transfected cells. 254 
Analysis of the array data revealed only a moderate effect on overall gene expression, 255 
with just 29 genes being modulated by more than 1.2 fold (supplementary table I and 256 
Fig. 2A). However, of these genes, 20 (69%) contained miR-29 binding sites within 257 
their 3’ UTRs, suggesting potential for direct targeting by miR-29 (Fig. 2B). Further 258 
analysis of the genes with miR29 binding sites revealed that 16 (80%) of the seed 259 
regions contained either 8mers (an exact match to positions 1-8 of the mature miRNA 260 
including an A opposite position 1 of the miRNA) or 7mers (an exact match to positions 261 
2-8 of the mature miRNA) (Fig. 2B).  262 
 263 
Although, a 15 fold overexpression of miR-29 is non-physiological, the incorporation 264 
of miR into “active” RISC complexes is known to be far lower than cytoplasmic levels 265 
(Flores et al., 2014). Despite this, these data demonstrate the potential for miR-29 to 266 
regulate a number of  genes of interest to B cell regulation. We observed that AICDA 267 
was one of the top target genes repressed by miR-29 overexpression, while the 268 
previously validated miR-29b target, CDK6 (Zhao et al., 2010), was also robustly 269 
repressed (Fig. 2A, C). Other validated miR-29 targets repressed following miR-29b 270 
overexpression in tonsil B cells included the guanine exchange factor RCC2 (Matsuo 271 
et al., 2013), the thymine glycosylase TDG (Morita et al., 2013; P. Zhang et al., 2013) 272 
and the trafficking protein TRAK2 (Kato et al., 2016) (Fig. 2C).  273 
 274 
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Given its indispensable role in promoting B cell antibody diversification, the repression 275 
of AICDA following miR-29b overexpression was of particular interest. To further 276 
explore the potential regulation of AICDA by miR-29b, tonsil B cells were transfected 277 
with a miR-29b mimic and cultured in the presence of IL-4 and anti-CD40 antibody to 278 
induce AICDA expression CSR and plasmablast differentiation; as previously 279 
demonstrated this resulted in an 15 fold increase in miR29b levels, supplementary 280 
figure 3A). RNA was isolated 24 hours after transfection and the expression of a series 281 
of miR-29 targets associated with either CSR-, GC- and plasma cell differentiation and 282 
function, including AICDA, were assessed via qRT-PCR.  283 
 284 
In line with the array data, AICDA was consistently repressed by over 2-fold following 285 
miR-29b overexpression (Fig. 3A). Similarly, the bona fide miR-29 target, CDK6 286 
(Zhao et al., 2010), was also robustly reduced following miR-29b overexpression, 287 
demonstrating the biological validity of these experiments (Fig. 3A). However, two 288 
previously reported miR-29 targets, AKT3 (Wei et al., 2013) and SP1 (Jia et al., 2014), 289 
remained unperturbed (Fig. 3A), suggesting that in the context of human B cells, they 290 
are not subject to miR-29b repression at the transcript level. The expression levels of 291 
BATF (Ise et al., 2011), HOXC4 (Park et al., 2009), MYC (Fernandez et al., 2013) and 292 
IRF4 ((Luo and Tian, 2010), previously reported to directly regulate AID transcription, 293 
and the expression of factors critical to the GC/PB phenotype (BCL6, PAX5, XBP1 294 
and BLIMP1) were all perturbed by >20%, although BATF, XBP1 and MYC did show 295 
small but reproducible decreases.  296 
 297 
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The repression of AICDA mRNA following miR-29b overexpression was also mirrored 298 
at the protein level. Immunoblotting 60 hours post transfection using the EK2 5G9 anti-299 
AID monoclonal antibody showed a clear reduction in AID protein (Fig. 3B). 300 
Densitometry revealed this to be an approximate 60% decrease, indicating a strong 301 
correlation between mRNA and protein expression changes (Fig. 3B). Overall, the data 302 
show that the overexpression of miR-29 in tonsil B cells activated to express AID was 303 
indeed capable of repressing AID expression at both the protein and mRNA level. 304 
 305 
3.3 Knockdown of miR-29b in activated naïve B cells augments AID expression 306 
To gain further insight into the role of miR-29b in the context of B cell activation, naive 307 
B cells, which express endogenous miR-29b, were transfected with a commercial miR-308 
29 inhibitor (see methods for details) or non-silencing control and cultured with IL-4 309 
and anti-CD40 stimulation. Delivery of the inhibitor repressed endogenous miR-29b by 310 
approximately 2 fold (as assessed by qPCR) when compared to B cells transfected with 311 
a negative control, and lasted for approximately 48 hours before beginning to recover 312 
(supplementary Fig. 3B). This repression of miR-29 represents a far more 313 
physiological, and therefore biologically relevant, manipulation; bringing miR-29 314 
expression down to a similar level to that seen in tonsil B cells (3-fold lower than naïve 315 
B cells). As in total B cell experiments, no detectable difference was seen in cell 316 
viability between the miR29b inhibitor or non-silencing control as judged by flow 317 
cytometry FSC/SSC although cell viability was reduced approximately 2 fold 318 
compared to un-transfected cells. The biological consequences of this inhibition were 319 
assessed by monitoring the expression of AICDA as well as CSR, GC and plasma cell 320 
associated genes and three previously validated miR-29 targets, by qRT-PCR.  321 
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 322 
In a reciprocal manner to the miR-29b overexpression results, we observed that AICDA 323 
was significantly increased following 60% miR-29b inhibition (supplementary Figure 324 
3B & Fig. 4A). Similarly, expression of the previously validated miR-29 target, CDK6 325 
(Zhao et al., 2010) and MYC, previously indirectly linked to miR-29 (S. Liu et al., 326 
2010), were elevated. Although a modest increase in GLT expression was detected 327 
following miR29 knockdown this was not found to be significant compared to the 328 
control. Also in line with our overexpression analysis, the reported miR-29 targets, 329 
AKT3 (Wei et al., 2013) and SP1 (Garzon et al., 2009), were unaltered following miR-330 
29b inhibition (Fig. 4A).  331 
To determine whether the elevated AICDA mRNA expression was reflected at the 332 
protein level, we performed immunoblots 60 hours post transfection. Further 333 
confirming the effect at the mRNA level, we observed that AID protein expression was 334 
increased by 1.6-fold following miR-29b inhibition, as determined via densitometry 335 
(Fig. 4B). Together, these data demonstrate that even reducing the physiological levels 336 
of miR-29 expression found in naïve B cells less than that seen in tonsil B cells (which 337 
express 3 fold less miR-29 than naïve B cells rather than the 2 fold reduction induced) 338 
is sufficient to de-repress AID in circulating naïve B cells. 339 
 340 
3.4 miR-29b directly targets the miR-29 binding site within the AICDA 3’ UTR  341 
To investigate the possibility that AID may be indirectly regulated by miR-29b, the 342 
expression of a number of signalling components of the B cell activation pathway were 343 
investigated to determine the impact of potential indirect modes of regulation. 344 
Following miR-29b manipulation, the expression and phosphorylation of members of 345 
 16 
the PI3K, MAPK and STAT6 pathway were found to be unperturbed (supplementary 346 
Fig. 3C). This further confirmed that miR-29b is likely directly targeting AICDA. 347 
Bioinformatic analysis of the human AICDA 3’ UTR revealed the presence of a 348 
pronounced miR-29 binding site (Fig. 5A). This site is found in the AICDA 3’ UTR of 349 
other primate species, such as chimpanzees and rhesus macaques, but not in more 350 
distantly related mammals, such as mice, rats and rabbits. The miR-29 binding site in 351 
the AICDA 3’ UTR shows complementarity from nucleotides 1-10 at the 5’ end of the 352 
miRNA, and includes an adenosine opposite position 1 (Fig. 5A). Seed region 353 
complementarity and an adenosine opposite position 1 are both strong indicators of 354 
miRNA targeting (Agarwal et al., 2015). In addition, the site is located in a favourable 355 
genomic context, it is under 200 nucleotides away from the 3’ end of the 3’ UTR, and 356 
embedded in an AU-rich environment. The miRNA targeting prediction tool 357 
TargetScan reported AICDA to be in the 4th percentile in terms of favourability for all 358 
miR-29 binding sites (not shown).  359 
 360 
Since AICDA possessed a strong miR-29b binding site in its 3’UTR, the direct targeting 361 
of AID by miR-29b was assessed. The region encapsulating the miR-29 binding site of 362 
the AICDA 3’UTR was sub-cloned into a luciferase reporter vector. Constructs in 363 
which the miR-29 binding site was mutated and replaced with a BamHI restriction site 364 
(Fig. 5A) and constructs containing no insert were used as negative controls. Each 365 
vector was separately cotransfected into HEK293 cells along with a miR-29b mimic 366 
molecule. Following 24 hours in culture, miR-29b was shown to be capable of 367 
repressing the luciferase activity of the test vector, relative to both negative control 368 
vectors (Fig. 5B). This demonstrated that miR-29b was indeed capable of directly 369 
interacting with the AICDA 3’ UTR and suppressing protein expression.  370 
 17 
 371 
3.5 miR-29 dampens CSR to IgE in stimulated tonsil B cells  372 
In order to mount a diversified humoral immune response, B cells not only undergo 373 
CSR and SHM but must also coordinate their proliferative and apoptotic potential 374 
(Recaldin and Fear, 2016). As such, the phenotypic consequences of miR-29b 375 
overexpression were assessed in both activated tonsil B cells and the CL01 germinal 376 
centre cell line. Following anti-CD40 and IL-4 stimulation, overexpression of miR-29b 377 
had no detectable effect on apoptosis or cell proliferation (supplementary Fig. 3D-F).  378 
 379 
Given that miR-29b modulates AID levels, we also investigated its effect on in vitro 380 
stimulated CSR. Although we show that transient transfection of naïve B cells could be 381 
successfully accomplished and that mir29b over-expression resulted in a robust 382 
diminution of induced AID expression, cells transfected with either the miRNA mimic 383 
or non-silencing control produced very little isotype switched immunoglobulin 384 
following 14 days culture. In order to demonstrate a biological consequence of 385 
miRNA29b diminished AID expression we overexpressed miR29b in total tonsillar B 386 
cells. CSR to IgE is most robustly stimulated in tonsil B cells following activation with 387 
IL-4 and anti-CD40(Ramadani et al., 2017; 2015) and we reasoned that although miR-388 
29b repression of AID is only transient (approx. 48 hours) in this system, this is the 389 
timepoint at which most AID is functionally active, and thus might affect CSR. When 390 
provided with anti-CD40 and IL-4 stimulation, tonsil B cells maintain their IgG 391 
expression, with switching to and from IgG being balanced, over the course of 7 days, 392 
but significantly increase switching to IgE from negligible to detectable levels, and thus 393 
can be tracked via flow cytometry (Ramadani et al., 2015). Assessment of Ig gene 394 
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expression in B cell cultures by qRT-PCR, 5 days after transfection with a miR-29b 395 
mimic, revealed a moderate but reproducible, 30% decrease in IgE mRNA (Fig. 6A). 396 
After 7 days in culture, IL-4 and anti-CD40 stimulated B cells transfected with either 397 
the miR29b mimic or non-silencing control were similarly viable (cell viability 10.3% 398 
+/- 2.2 versus 11.2% 
+/- 2.0), although viability was reduced 2.5 fold compared to 399 
similarly stimulated un-transfected cells(Ramadani et al., 2015). Intracellular staining 400 
of immunoglobulin protein at day 7 reproduced a similar moderate but statistically 401 
significant reduction in the percentage of IgE-expressing cells (Fig. 6B). The 402 
percentage of IgG-expressing cells was not significantly altered (Fig. 6B). Knockdown 403 
of AID through use of a short-interfering RNA to AICDA resulted in a similar pattern 404 
of Ig expression; giving a small but reproducible reduction in the percentage of IgE-405 
expressing cells, but no significant alteration in IgG-expressing cells (Fig. 6C). 406 
Demonstrating that miR-29 OE not only modulates AID expression but is able to illicit 407 
a biologically relevant functional effect. Together these results demonstrated that miR-408 
29b, a miRNA downregulated in activated B cells, is capable of directly targeting 409 
AICDA mRNA, and decreases CSR to IgE following stimulation with IL-4 and anti-410 
CD40 antibody. We posit that miR 29 represents a previously unrecognised player in 411 
human B cell biology that warrants further investigation.   412 
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4. Discussion 413 
miRNAs play an important role in fine tuning cells’ protein output and have previously 414 
been shown to regulate important aspects of B cell biology (Taganov et al., 2007). 415 
However, the functional role of miRNAs have not been extensively studied in the 416 
activation of human B cells. This study sought to identify miRNAs that were 417 
dynamically and temporally regulated between different mature B cell subpopulations, 418 
and identify their functional consequences in the development of the humoral response. 419 
Previous studies have used PCR, microarray or RNA-seq to monitor the miRNA 420 
expression changes that occur during the course of a B cell response, predominantly 421 
focusing on the differences between naïve, GC and memory B cells found within the 422 
same secondary lymphoid organs (Basso et al., 2009; Malumbres et al., 2009; Tan et 423 
al., 2009; J. Zhang et al., 2009).  The original data from Malumbres et al., (Malumbres 424 
et al., 2009) indicated that miR-29b, a member of the miR-29 family that is important 425 
in coordinating the lymphocyte response to intracellular pathogens such as Listeria 426 
monocytogenes (Ma et al., 2011), was repressed in the GC compartment. Interrogation 427 
of data from other papers that analysed the human B cell miRNome (Basso et al., 2009; 428 
Tan et al., 2009; J. Zhang et al., 2009) confirmed this observation. The miR-29 family 429 
of miRNAs are known to be particularly important in T cells, where they control aspects 430 
of development and effector function (Ma et al., 2011; Papadopoulou et al., 2011; 431 
Steiner et al., 2011), and in B cells have recently been shown to regulate germinal centre 432 
dynamics in a murine model of collagen-induced arthritis (Nieuwenhuijze, 2017). 433 
However, the functional consequences of this miRNA in naïve human B cells and B 434 
cell activation have not previously been studied. 435 
 436 
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Here, we found that mature miR-29b was approximately 3-fold less abundant in B cells 437 
isolated from tonsil lymphoid tissue than in circulating naïve B cells isolated from 438 
blood, confirming that miR-29b was dynamically regulated upon exit from the 439 
circulation and entry into the lymphoid tissue. In order to identify miR-29b’s function 440 
in this context and identify potential target molecules, it was overexpressed through the 441 
use of miRNA mimic molecules and global gene expression changes monitored by 442 
microarray analysis. This revealed that the second most dynamically regulated gene 443 
following miR-29b overexpression, after the eukaryotic initiation factor EIF4E2, was 444 
found to be AICDA, which plays a critical role in B cell biology (Fig. 2A, B). 445 
Considering that AID is also a potent genome mutator and has oncogenic potential 446 
(Robbiani et al., 2009; 2008) its expression and activity must be carefully regulated. In 447 
mice, Aicda is post-transcriptionally regulated by miR-155 and miR-181b (de Yebenes 448 
et al., 2008; Dorsett et al., 2008; Teng et al., 2008). However, regulation of AICDA by 449 
different miRNA members has not been fully investigated in human B cells. 450 
 451 
The human AICDA 3’ UTR contains a pronounced miR-29 binding site with extensive 452 
complementarity, indicating the possibility of a direct interaction. This is confirmed by 453 
our results which show that over expression of a miR-29b mimic represses luciferase 454 
activity in HEK293 cells transfected with a luciferase reporter construct containing the 455 
region of AICDA 3’ UTR bearing the miR-29 binding site (Fig. 5B) while miR-29b 456 
overexpression in tonsil B cells significantly reduced AICDA expression, AID protein 457 
levels (Fig. 3) and CSR to IgE (Fig. 6). Although we cannot rule out additional indirect 458 
mechanisms of miR-29b eliciting a response on both AID expression and CSR to IgE, 459 
miR-29b OE did not affect the expression of apoptotic markers in either tonsil b cells 460 
(as evidenced by the microarray study) or a B cell line (Supplementary figure 3E) and 461 
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did not affect cell proliferation (Supplementary figure 3F). This raises the question as 462 
to the purpose of such an interaction. AID and miR-29b expression are inversely 463 
correlated. AICDA is detectable in the lymphoid follicles and most abundant in GC B 464 
cells, but absent in circulating naïve B cells. Conversely, miR-29b is reduced in the 465 
follicles but prominent in circulating naïve B cells. This indicates that the function of 466 
miR-29b may be to suppress premature AID at the early stages of a mature B cell’s life 467 
cycle, or following inappropriate activation in the absence of suitable T cell help or T-468 
independent “danger” signals.  469 
 470 
Upon entry into the lymphoid tissue and subsequently the GC, where AID expression 471 
is appropriate, the down regulation of miR-29b would relieve the block on AICDA and 472 
allow its full regulated expression. Indeed, the potential of endogenous miR-29b to 473 
regulate AID in this context was demonstrated by the increase of AID mRNA and 474 
protein expression levels when miR-29b was inhibited in IL4 and antiCD40 stimulated 475 
naïve B cells (Fig. 4A and 2B). We believe this to be a far more compelling result 476 
(being carried out at a physiologically relevant level of miR-29b) than the 477 
overexpression study and evidence of the potential for miR-29b to regulate AID 478 
expression. In contrast, in tonsil B cells, where miR-29b is less abundant, miR29b 479 
inhibitors did not elevate AICDA (data not shown). This strongly suggests that while 480 
endogenous miR-29b expression in naïve B cells is sufficient to suppress AICDA 481 
expression, the low levels of miR-29b in GC B cells is insufficient to do so (although 482 
overexpression of miR29b above physiological levels does indeed strongly repressing 483 
AID and partially blocks CSR). As such, it is likely that miR-29b is able to repress 484 
leaky or inappropriate expression of AID prior to B cell activation. In relation to 485 
miR29s potential role in preventing inappropriate AID expression, and therefore 486 
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function, in naïve B cells, it of interest to note that miR29 (a, b and c) was found to be 487 
decreased in Mantle cell lymphoma (MCL) (Zhao et al., 2010), a lymphoma with 488 
characteristics of CD5+, antigen-naive pregerminal center B-cells. Although Cyclin D1 489 
translocation and the up-regulation of CDK6 (a direct miR29 target) is thought to 490 
account for the transformation of MCL cells, they were also found to frequently express 491 
AID possibly accounting for at least some of wide range of chromosomal abnormalities 492 
present in this disease(Babbage et al., 2004).  493 
 494 
Following B cell exit from the circulation, miR-29b silencing in GC B cells leads to a 495 
de-repression of AICDA transcription. Such a model has been previously ascribed to 496 
miR-181b regulation of aicda in mice (de Yebenes et al., 2008). Interestingly, miR29c 497 
shares a similar expression pattern to miR-29b, being most highly expressed in naïve B 498 
cells and low in GC B cells (Supplementary Figure 1). Since miR29 family members 499 
share seed region homology and therefore predicted targets, the expression of these 500 
miRs would be expected to reinforce their functional effects. It should be noted that the 501 
miR-29 site in the AICDA 3’ UTR is conserved amongst other primate species, but not 502 
in more distantly related mammals, such as mice, rats and rabbits. Thus, it is not an 503 
interaction that has been strongly conserved throughout mammalian evolution and may 504 
have arisen more recently. 505 
In conclusion, the data in this paper have shown that miR-29b, a member of the 506 
conserved miR-29 family, is repressed in tonsil B cells relative to circulating naïve B 507 
cells. Enforced overexpression of miR-29b in tonsil B cells led to the direct targeting 508 
of AICDA, through a pronounced binding site in the AICDA 3’ UTR and this interaction 509 
was sufficient to reduce CSR to IgE. Similarly, inhibition of endogenous miR-29b in 510 
naïve B cells resulted in elevated AID expression. We hypothesise that one of the 511 
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endogenous functions of miR-29 is to silence leaky expression of AID, a mutagenic 512 
protein whose expression must be controlled in order to maintain chromosomal 513 
integrity. 514 
  515 
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Figure legends 754 
 755 
Figure 1: miR-29 is less abundant in B cells isolated from tonsillar tissue than in 756 
naïve B cells isolated from peripheral blood. 757 
The expression level of miR-29 in IgD+ CD27- naive B cells isolated from peripheral 758 
blood compared to CD19+ tonsil B cells, as assessed via qRT-PCR. Values are plotted 759 
relative to the small nucleolar RNA RNU6B. ** P < 0.01(unpaired t-test). 760 
 761 
Figure 2: Genome-wide analysis of miR-29b targeting in tonsillar B cells shows an 762 
enrichment in miR-29 binding sites within the 3’ UTR of downregulated genes. 763 
(A) Heatmap representing expression changes in the most downregulated genes in 764 
tonsillar B cells transfected with a miR-29 mimic and stimulated with anti-CD40 765 
antibody and IL-4 cytokine for 24 hours, as detected by Illumina BeadChip Array. 766 
Genes containing predicted miR-29 binding sites in their 3’ UTR are listed in red. P 767 
values (two-way ANOVA) are also included. 768 
(B) Pie chart displaying the prevalence of miR-29 binding sites within the 3’ UTR of 769 
genes downregulated following miR-29b overexpression. The percentage of 8mers (an 770 
exact match to positions 2-8 of the mature miRNA with an A opposite position 1 of the 771 
miRNA), 7mer-m8s (an exact match to positions 2-8 of the mature miRNA) and 6mers 772 
(an exact match to positions 2-7 of the mature miRNA) within the miR-29 binding sites 773 
is also shown. 774 
(C) Dot plot representations of the change in fluorescence intensity for AICDA, as well 775 
as previously validated targets including CDK6, RCC1, TDG and TRAK2, in tonsil B 776 
cells transfected with a miR-29 mimic and stimulated with anti-CD40 antibody and IL-777 
4 cytokine for 24 hours, as detected by Illumina BeadChip Array. 778 
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Figure 3: Overexpression of miR-29 reduces AID abundance in tonsillar B cells. 779 
tonsil B cells were transfected with a miR-29b mimic or its associated negative control 780 
molecule and subsequently activated with IL-4 and anti-CD40. 781 
(A) Gene expression of key B cell molecules after 24 hours of stimulation as assessed 782 
via qRT-PCR. Values are normalized to 18S ribosomal RNA and plotted relative to the 783 
abundance of each gene in the control transfected cells, which were arbitrarily assigned 784 
a value of 1. N = 3 - 12, mean and s.e.m. * P <0.05, ** P < 0.01, **** P < 0.0001 785 
(paired t-test). 786 
(B) Representative immunoblot and cumulative densitometry analysis (n = 3) of AID 787 
protein in follicular B cells following miR-29b overexpression and 60h of culture in 788 
IL-4 and anti-CD40 stimulus, compared to AID protein in the control transfected cells. 789 
GAPDH served as a loading control. 790 
 791 
Figure 4: Knockdown of miR-29 increases AID abundance in naïve B cells. 792 
Naive B cells were transfected with a miR-29 inhibitor or its associated negative control 793 
molecule and subsequently activated with IL-4 and anti-CD40. 794 
(A) Gene expression of key B cell molecules after 48 hours of stimulation as assessed 795 
via qRT-PCR. Values were normalized to 18S ribosomal RNA and plotted relative to 796 
the abundance of each gene in the control transfected cells, which were arbitrarily 797 
assigned a value of 1. N = 6 - 12. Mean and s.e.m. ** P < 0.01, *** P < 0.001, **** P 798 
< 0.0001 (paired t-test). 799 
(B) Representative immunoblot and cumulative densitometry analysis (n = 3) of AID 800 
protein in naïve B cells following miR-29b knockdown and 60h of culture in IL-4 and 801 
anti-CD40 stimulus, compared to AID protein in the control transfected cells. GAPDH 802 
served as a loading control. 803 
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 804 
Figure 5: miR-29 is capable of directly targeting the miR-29 binding site within 805 
the AICDA 3’ UTR. 806 
(A) The miR-29 binding site within the human, chimpanzee and rhesus macaque 807 
AICDA 3’ UTR, as well as the mismatched sequence used for luciferase analysis. 808 
(B) HEK293T cells were contransfected with one of the dual luciferase plasmids 809 
(endogenous AICDA 3’ UTR, mismatched 3’ UTR or no insert) and a miR-29 mimic. 810 
Firefly luciferase activity was quantified after 24 hours, normalized to renilla luciferase 811 
and plotted relative to the no insert plasmid. * P < 0.05 (one-way ANOVA). N = 3, 812 
mean and s.e.m. 813 
 814 
Figure 6: miR-29 overexpression dampens induction of class switching to IgE. 815 
Tonsil B cells were transfected with a miR-29 mimic or negative control molecules and 816 
subsequently cultured in class-switching conditions (IL-4 and ati-CD40 antibody). 817 
(A) IgE and IgG mRNA were detected via qRT-PCR following 5 days of culture. 818 
Values are plotted relative to 18S ribosomal RNA.  N = 7 for IgE and 5 for IgG, mean 819 
and s.e.m. 820 
(B) Intracellular IgE and IgG was analysed following 7 days of culture via flow 821 
cytometry. * P < 0.05 (paired t test). 822 
(C) Intracellular IgE and IgG was analysed following 7 days of culture via flow 823 
cytometry. Values were plotted relative to the control transfected cells, which were 824 
arbitrarily assigned a value of 1. N = 3 for siAID, and 10 for miR-29 versus the negative 825 
control mimic. * P < 0.05 (paired t test). Mean and s.e.m. 826 
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